Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;27(2):e226-e230.
doi: 10.3747/co.27.6245. Epub 2020 May 1.

The Canadian Cancer Research Conference 2019

K J C Galpin  1   2 , D P Cook  1   2 , L M Salemi  3 , S Urowitz  3 , C Williams  4 , J C Bell  2   5 , M D Brundage  1   2   3   4   5   6 , B C Vanderhyden  1   2
Affiliations

The Canadian Cancer Research Conference 2019

K J C Galpin et al. Curr Oncol. 2020 Apr.

Abstract

The 5th Canadian Cancer Research Conference (ccrc) took place 3-5 November 2019 in Ottawa, Ontario. Nearly 1000 participants-scientists, oncologists, community members, and patients-gathered to share knowledge, foster collaboration, and fuel the future of cancer research in Canada. The scientific program included 3 plenary sessions, 26 concurrent sessions, and 2 poster sessions presenting research described in more than 600 submitted abstracts, giving participants the opportunity to share health research that collectively encompassed the 4 pillars recognized by the Canadian Institutes of Health Research. In addition to the breadth of topics addressed by Canadian and international experts, the highlights of the meeting included the integration of patients and patient advocates, new rapid-fire sessions for abstract presentation, and events that enhanced learning opportunities for trainees.

Keywords: Cancer research; meetings; patient engagement.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare that we have none relevant to this report.

References

    1. Kruger S, Ilmer M, Kobold S, et al. Advances in cancer immunotherapy 2019—latest trends. J Exp Clin Cancer Res. 2019;38:268. doi: 10.1186/s13046-019-1266-0. - DOI - PMC - PubMed
    1. Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197–218. doi: 10.1038/s41573-018-0007-y. - DOI - PubMed
    1. Chae YK, Pan AP, Davis AA, et al. Path toward precision oncology: review of targeted therapy studies and tools to aid in defining “actionability” of a molecular lesion and patient management support. Mol Cancer Ther. 2017;16:2645–55. doi: 10.1158/1535-7163.MCT-17-0597. - DOI - PubMed
    1. Loomans-Kropp HA, Umar A. Cancer prevention and screening: the next step in the era of precision medicine. NPJ Precision Oncology. 2019;3:3. doi: 10.1038/s41698-018-0075-9. - DOI - PMC - PubMed